






Fig. 1






Fig. 3A




Fig. 3B

Cyno#	Extra Nucleic Information Acid Conc.		LCV qPCR Result				SCMV qPCR Result			
	ng/ul	Ct #1	Ct #2	Ct #3	Mean Ct	Std Ct	Mean Qiy	Mean Qiy	Mean Qiy	Mean Qiy
Group 1										
1-103093M	D-14	32.2	U	51.14	51.21	51.18	0.06	0.42	20.78	U
1001-100431M	D-14	43.1	U	U	U	U	U	U	U	U
1002-101079M	D-14	36.5	46.26	47.17	47.70	47.04	0.73	4.16	207.87	U
1003-100807M	D-14	22.7	U	48.55	47.93	48.24	0.46	2.08	104.04	U
1004-100805M	D-14	39.4	42.33	43.01	44.08	43.14	0.89	35.43	171.27	U
1005-100103M	D-14	31.8	41.92	42.05	42.62	42.19	0.57	55.73	2786.51	U
Group 2										
2001-091209M	D-14	65.6	48.96	51.52	48.65	49.71	1.57	1.12	56.22	U
2002-110307M	D-14	53.2	52.62	54.36	U	53.49	1.23	0.13	6.58	U
2003-201103M	D-14	38.1	48.35	50.72	51.98	50.35	1.84	0.91	45.54	U
2004-102855M	D-14	26.7	47.24	48.45	49.94	48.54	1.35	2.07	103.32	U
2005-101005M	D-14	34.3	48.08	52.51	52.11	50.90	2.45	0.90	44.91	U
Group 3										
3001-100909M	D-14	32.1	46.69	47.72	52.65	49.01	3.17	2.56	128.10	U
3002-103087M	D-14	45.6	48.95	48.52	50.31	49.29	0.90	1.24	62.19	U
3003-101105M	D-14	47.2	47.88	48.27	50.62	48.92	1.40	1.70	84.80	U
3004-100608M	D-14	39.9	U	U	53.21	53.21	U	0.14	6.88	U
3005-100505M	D-14	48.2	54.34	52.19	51.39	52.64	1.53	0.23	11.40	U
Group 4										
4001-100403M	D-14	54.2	U	54.15	51.33	52.74	1.89	0.23	11.63	U
4002-100433M	D-14	31.1	U	U	U	U	U	U	U	U
4003-100807M	D-14	30.5	U	U	U	U	U	U	U	U
4004-101183M	D-14	46.5	52.19	U	46.57	50.88	1.86	0.62	30.94	U
4005-101205M	D-14	19.4	U	48.40	U	48.40	U	1.88	94.74	U

Fig. 4

Model Assumptions






Fig. 5



- * A serum exposure target of 52 $\mu\text{g/mL}$ was estimated by modeling the tumor volume suppression in syngeneic mice
- * A clinical dose of 15 mg/kg administered IV every other week is predicted to provide target exposure coverage during the 14-day dosing period

Fig. 6B



- Single dose IV PK in Cynomolgus Monkey (n=5)**
- Key points:**
- Non-linearity in PK observed with increasing dose
 - * Clearance decreased (363 to 8 mL/day/kg)
 - * Half-life increased (0.2 to 10 days)
 - Saturation of the sink at serum concentrations above $\sim 40 \mu\text{g/mL}$ ($K_m = 2 \mu\text{g/mL}$)

Fig. 6A




Fig. 7B

Fig. 7A






Fig. 8






Fig. 10B

Fig. 10A




Fig. 10C

Tumor CD73




Fig. 11B




Fig. 11A




Fig. 11C




Fig. 12




Fig. 13




Fig. 14A




Fig. 14B




Fig. 15




Fig. 16




Fig. 17




Fig. 18




Fig. 19




Fig. 20




Fig. 21




Fig. 22




Fig. 23




Fig. 24A




Fig. 24B




Fig. 24C




Fig. 24D




Fig. 25A




Fig. 25B




Fig. 26A




Fig. 26B




Fig. 26C




Fig. 27












Fig. 28








Fig. 29I




Fig. 30

Fig. 31A Isotype Control & Vehicle




Fig. 31B anti-PD-L1




Fig. 31C anti-CD73




Fig. 31D Docetaxel




Fig. 31F anti-CD73 + Docetaxel




Fig. 31H anti-PD-L1 + anti-CD73 + Docetaxel




Fig. 31E anti-PD-L1 + Docetaxel





Fig. 31G anti-PD-L1 + anti-CD73






Fig. 31I

Fig. 32B





Fig. 32A







Fig. 32F

anti-CD73 + 5FU + OHP




Fig. 32E

anti-PD-L1 + 5FU + OHP




Fig. 32H

anti-PD-L1 + anti-CD73 + 5FU + OHP




Fig. 32G

anti-PD-L1 + anti-CD73

